Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76


Estrogen receptors α and β and aromatase as independent predictors for prostate cancer outcome.

Grindstad T, Skjefstad K, Andersen S, Ness N, Nordby Y, Al-Saad S, Fismen S, Donnem T, Khanehkenari MR, Busund LT, Bremnes RM, Richardsen E.

Sci Rep. 2016 Sep 9;6:33114. doi: 10.1038/srep33114.


Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma.

Baker CB, McDonald AM, Yang ES, Jacob R, Rais-Bahrami S, Nix JW, Fiveash JB.

Prostate Cancer. 2016;2016:2674954. doi: 10.1155/2016/2674954. Epub 2016 Mar 9.


UHRF1 overexpression is involved in cell proliferation and biochemical recurrence in prostate cancer after radical prostatectomy.

Wan X, Yang S, Huang W, Wu D, Chen H, Wu M, Li J, Li T, Li Y.

J Exp Clin Cancer Res. 2016 Feb 17;35:34. doi: 10.1186/s13046-016-0308-0.


Biochemical recurrence risk factors in surgically treated high and very high-risk prostate tumors.

Aguilera A, Bañuelos B, Díez J, Alonso-Dorrego JM, Cisneros J, Peña J.

Cent European J Urol. 2015;68(3):302-7. doi: 10.5173/ceju.2015.485. Epub 2015 Sep 26.


Radical Prostatectomy versus External Beam Radiotherapy for cT1-4N0M0 Prostate Cancer: Comparison of Patient Outcomes Including Mortality.

Taguchi S, Fukuhara H, Shiraishi K, Nakagawa K, Morikawa T, Kakutani S, Takeshima Y, Miyazaki H, Fujimura T, Nakagawa T, Kume H, Homma Y.

PLoS One. 2015 Oct 27;10(10):e0141123. doi: 10.1371/journal.pone.0141123. eCollection 2015.


Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy.

Ün S, Türk H, Koca O, Divrik RT, Zorlu F.

Turk J Urol. 2015 Jun;41(2):61-6. doi: 10.5152/tud.2015.65624.


Role of Surgery in locally advanced prostate cancer.

Nazim SM, Abbas F.

Pak J Med Sci. 2015;31(3):710-6. doi: 10.12669/pjms.313.7103. Review.


An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality.

Sullivan J, Kopp R, Stratton K, Manschreck C, Corines M, Rau-Murthy R, Hayes J, Lincon A, Ashraf A, Thomas T, Schrader K, Gallagher D, Hamilton R, Scher H, Lilja H, Scardino P, Eastham J, Offit K, Vijai J, Klein RJ.

Br J Cancer. 2015 Jun 30;113(1):166-72. doi: 10.1038/bjc.2015.199. Epub 2015 Jun 11.


Versican is a potential therapeutic target in docetaxel-resistant prostate cancer.

Arichi N, Mitsui Y, Hiraki M, Nakamura S, Hiraoka T, Sumura M, Hirata H, Tanaka Y, Dahiya R, Yasumoto H, Shiina H.

Oncoscience. 2015 Mar 2;2(2):193-204. eCollection 2015.


High progesterone receptor expression in prostate cancer is associated with clinical failure.

Grindstad T, Andersen S, Al-Saad S, Donnem T, Kiselev Y, Nordahl Melbø-Jørgensen C, Skjefstad K, Busund LT, Bremnes RM, Richardsen E.

PLoS One. 2015 Feb 27;10(2):e0116691. doi: 10.1371/journal.pone.0116691. eCollection 2015.


Time from first detectable PSA following radical prostatectomy to biochemical recurrence: A competing risk analysis.

de Boo L, Pintilie M, Yip P, Baniel J, Fleshner N, Margel D.

Can Urol Assoc J. 2015 Jan-Feb;9(1-2):E14-21. doi: 10.5489/cuaj.2147.


Clinical management and burden of prostate cancer: a Markov Monte Carlo model.

Sanyal C, Aprikian A, Cury F, Chevalier S, Dragomir A.

PLoS One. 2014 Dec 4;9(12):e113432. doi: 10.1371/journal.pone.0113432. eCollection 2014.


Outcome of postoperative radiotherapy following radical prostatectomy: a single institutional experience.

Lee SW, Hwang TK, Hong SH, Lee JY, Chung MJ, Jeong SM, Kim SH, Lee JH, Jang HS, Yoon SC.

Radiat Oncol J. 2014 Sep;32(3):138-46. doi: 10.3857/roj.2014.32.3.138. Epub 2014 Sep 30.


MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients' samples.

Cannistraci A, Di Pace AL, De Maria R, Bonci D.

Biomed Res Int. 2014;2014:146170. doi: 10.1155/2014/146170. Epub 2014 Sep 16. Review.


Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.

Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco FJ Jr, Rabah DM, Klein EA, Ciezki JP, Gao T, Kattan MW, Stephenson AJ.

Eur Urol. 2015 Jun;67(6):1160-7. doi: 10.1016/j.eururo.2014.09.019. Epub 2014 Oct 6.


Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.

Gordon RR, Wu M, Huang CY, Harris WP, Sim HG, Lucas JM, Coleman I, Higano CS, Gulati R, True LD, Vessella R, Lange PH, Garzotto M, Beer TM, Nelson PS.

PLoS One. 2014 Sep 8;9(9):e104271. doi: 10.1371/journal.pone.0104271. eCollection 2014.


An Incidental Finding of Mucinous Colon Cancer by (18)F-Choline PET/CT Determining a Change in Clinical Management of a Patient with Recurrent Prostate Adenocarcinoma.

Tuscano C, Russi EG, Al Sayyad S, Pergolizzi S.

Case Rep Oncol Med. 2014;2014:297031. doi: 10.1155/2014/297031. Epub 2014 Aug 13.


Predictive clinical indicators of biochemical progression in advanced prostate cancer patients receiving Leuplin depot as androgen deprivation therapy.

Chen CH, Hsieh JT, Huang KH, Pu YS, Chang HC.

PLoS One. 2014 Aug 14;9(8):e105091. doi: 10.1371/journal.pone.0105091. eCollection 2014.


Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'.

Ahmed KA, Davis BJ, Mynderse LA, Slezak JM, Bergstralh EJ, Wilson TM, Choo CR.

Radiat Oncol. 2014 Jul 29;9:171. doi: 10.1186/1748-717X-9-171.


Pre- and post-operative nomograms to predict recurrence-free probability in korean men with clinically localized prostate cancer.

Kang M, Jeong CW, Choi WS, Park YH, Cho SY, Lee S, Lee SB, Ku JH, Hong SK, Byun SS, Jeong H, Kwak C, Kim HH, Lee E, Lee SE; Seoul National University-Uro-Oncology Group.

PLoS One. 2014 Jun 17;9(6):e100053. doi: 10.1371/journal.pone.0100053. eCollection 2014.

Items per page

Supplemental Content

Write to the Help Desk